The primary challenge in treating gliomas is the blood–brain barrier (BBB)-mediated limitation of drug delivery together ity that promotes tumor cell survival

Gene therapy represents a transformative approach for treating genetic and acquired disorders, yet its clinical advancement faces significant obstacles associated with viral vectors, including immunogenicity, insertional mutagenesis, and production limitations. Non-viral gene delivery systems have emerged as promising safer and more versatile alternatives to overcome these challenges. These innovative platforms encompass lipid-based nanoparticles, polymeric carriers, dendrimers, inorganic nanocarriers, and hybrid formulations, offering enhanced flexibility and reduced safety risks. This comprehensive review examines the development and optimization of non-viral delivery systems for effective gene therapy, addressing critical considerations for achieving both safety and efficacy in clinical applications. The findings underscore the significant potential of non-viral approaches in advancing therapeutic gene delivery strategies.

Researchers developed an innovative folic acid-targeted liposomal delivery system for coencapsulation of doxorubicin and curcumin to overcome multidrug resistance in glioma treatment. The formulation achieved uniform size of 112.5 nm with high dual-drug encapsulation efficiency and demonstrated 3.56-fold enhanced cellular uptake in drug-resistant cells compared to non-targeted alternatives. Curcumin effectively downregulated P-glycoprotein expression, restoring doxorubicin sensitivity and preventing drug efflux. In vivo studies revealed a 71.19 percent tumor volume reduction, substantially exceeding performance of free drugs and non-targeted liposomes. The folic acid ligand enabled selective tumor targeting through receptor-binding interactions and enhanced blood-brain barrier penetration. This dual-functional delivery system represents a promising therapeutic approach combining active targeting with multidrug resistance reversal for improved glioma treatment outcomes.

Tumor hypoxia presents a critical obstacle in cancer therapy, promoting progression, metastasis, and treatment resistance. Traditional oxygen supplementation approaches prove insufficient due to limited delivery efficiency and safety concerns. Emerging nanoplatforms offer promising solutions through three primary mechanisms: exogenous oxygen delivery, endogenous oxygen generation, and metabolic oxygen conservation. These innovative nanotechnology-based systems effectively remodel the tumor microenvironment and enhance multimodal synergistic therapies. This comprehensive review synthesizes current knowledge on tumor hypoxia mechanisms, details nanomedicine design principles, and examines the potential and challenges of these platforms in combination therapies, providing essential guidance for advancing precision cancer treatment strategies.

Chemoresistance significantly limits the effectiveness of conventional cancer therapy, largely due to complex tumor microenvironment factors including hypoxia, acidic pH, immune suppression, and dense extracellular matrices that impede drug penetration and promote therapeutic resistance. Contemporary anticancer strategies are increasingly shifting focus from direct tumor destruction toward dynamic modulation and conversion of the microenvironment itself. Intelligent nanomedicine has emerged as a transformative platform capable of responding to endogenous and exogenous stimuli such as pH, redox gradients, hypoxia, and enzymes to achieve site-specific drug delivery and controlled therapeutic activation. Stimuli-responsive nanocarriers not only enhance intratumoral drug accumulation and penetration but also actively remodel the microenvironment through immunomodulation, representing a paradigm shift in personalized cancer treatment strategies.

Epirubicin is efficacious in various solid tumors, but its use in glioblastoma (GBM) is limited by poor blood-brain barrier penetration, low tumor retention and ...

This comprehensive analysis examines stimuli-responsive materials in therapeutic development, reviewing over 90,000 publications and 1,000 clinical trials from 2014 to 2024. The study evaluates both external stimuli, including light, ultrasound, radiation, magnetic fields, and temperature, as well as internal triggers such as pH, redox reactions, and enzymes. Light-based therapeutics dominate the field at 44% of publications, while redox and enzyme activation lead internal stimulus applications. Emerging technologies utilizing nano- and microscale platforms show growing clinical interest in radiation, ultrasound, temperature, and magnetic actuation. The research identifies critical barriers to clinical translation, including inaccurate medical need assessment, excessive material complexity, inadequate tissue penetration, limited device accessibility, economic constraints, and adoption challenges. These findings provide essential guidance for advancing stimuli-responsive therapeutics toward successful clinical implementation.

The MC3T3-E1 cell line (RCB1126) from RIKEN BRC is a mouse-derived osteoblast precursor cell with infinite lifespan, originally deposited in 1994. These fibroblast-like cells differentiate into osteoblasts and produce collagen, making them valuable for bone research. Cultured as adherent cells in MEM ALPHA medium with 10% FBS, they require subculturing twice weekly at 37°C with 5% CO2. The line is free from mycoplasma contamination and has been extensively characterized through SSLP analysis. Basic research use is unrestricted; however, commercial applications and patent-related use require prior contact with RIKEN BRC. Over 1,374 publications have utilized this widely-recognized cell line since its establishment.

The tumor microenvironment has emerged as a critical orchestrator of cancer progression, therapeutic resistance, and immune evasion, fundamentally reframing cancer as an ecosystem disease. This comprehensive review synthesizes advances in understanding the cellular and acellular architecture of the tumor microenvironment, including cancer-associated fibroblasts, tumor-associated macrophages, vasculature, and extracellular matrix remodeling. The authors examine molecular mechanisms driving immunosuppression and adaptive resistance, encompassing metabolic reprogramming, epigenetic dysregulation, and microbiome interactions. The review highlights innovative therapeutic strategies, including nanotechnology-based delivery systems, advanced immunotherapies such as CAR-T cells and oncolytic viruses, metabolic modulators, stromal normalization, and microbiome interventions. Emerging tools like patient-derived organoids, tumor-on-chip systems, and artificial intelligence-driven multi-omics analysis enable personalized therapeutic prediction, offering promising approaches to overcome intratumoral heterogeneity and therapeutic resistance challenges.

This research explores the engineering and development of exosome-based gene therapies, examining the innovative tools and methodologies employed to optimize these promising therapeutic vehicles. The article addresses critical targets for treatment and integrates artificial intelligence applications to enhance therapy design and efficacy. Exosomes, naturally occurring extracellular vesicles, offer significant advantages as delivery systems for genetic material due to their biocompatibility and capacity to cross biological barriers. The study synthesizes current advances in exosome engineering alongside emerging AI technologies to identify new therapeutic opportunities and improve treatment outcomes across various diseases, positioning these approaches as transformative solutions in precision medicine and regenerative therapeutics.

Dissecting the Tumor Microenvironment in Response to Immune Checkpoint Inhibitors via Single-Cell and Spatial Transcriptomics. Clin. Exp. Metastasis 2024 ...

More specifically, EVs derived from glioblastoma cells have been shown to promote proliferation, stemness, mesenchymal transition, and therapeutic resistance ...

This research article explores intelligent CpG nanoplatforms as innovative therapeutic agents for targeted cancer immunotherapy and immune system remodeling. The study focuses on leveraging CpG oligonucleotides—immune-stimulating molecules—delivered through advanced nanoplatform technology to enhance anti-tumor immune responses. By strategically modulating the tumor immune microenvironment and triggering immunogenic cell death, these intelligent nanoplatforms represent a promising approach to improving cancer treatment efficacy. The research contributes to the expanding field of nanomedicine-based immunotherapy, offering potential clinical applications for more effective and targeted cancer management strategies.

Proteolysis-targeting chimeras (PROTACs) represent a transformative approach to targeted protein degradation, yet their clinical development faces significant obstacles related to physicochemical properties that impede bioavailability and cellular uptake. This review examines chemistry-guided delivery strategies designed to address these limitations by integrating medicinal chemistry with advanced delivery science. Key innovations include prodrug engineering with photo-responsive and enzyme-activated mechanisms, as well as sophisticated delivery vehicles such as lipid-based nanoparticles, polymeric scaffolds, and antibody-conjugate platforms. The emergence of modular self-assembly and membrane-targeting approaches demonstrates progress toward programmable therapeutics that optimize both target selectivity and pharmacokinetic performance, promising to accelerate PROTAC transition into clinical applications.

Glioblastoma remains a devastating malignancy with poor prognosis despite current treatments. Oncolytic viruses represent a promising immunotherapeutic approach, engineered to induce tumor cell death while stimulating antitumor immune responses. However, their clinical efficacy is hampered by delivery challenges, including the blood-brain barrier and complex tumor microenvironment. Hydrogels, composed of natural and synthetic polymers, offer a solution by enabling sustained therapeutic payload delivery and facilitating combination therapies with immune checkpoint inhibitors. This review examines advances and obstacles in oncolytic virus therapy, explores hydrogel-mediated delivery mechanisms, and discusses opportunities for hydrogel-based oncolytic virus and immune adjuvant combinations in treating glioblastoma and other high-grade brain tumors.

This comprehensive review examines the complex cellular landscape of the tumor microenvironment through single-cell atlas analysis. The article provides detailed insights into specialized cell subtypes and their coordinated network interactions that collectively influence tumor behavior and progression. By integrating single-cell sequencing data, researchers identify previously unknown cellular populations and elucidate their functional roles within tumors. The study emphasizes the immunological aspects of the microenvironment, with particular focus on how understanding these cellular networks can inform and enhance immunotherapy approaches. This open-access publication contributes significantly to advancing precision medicine by mapping cellular heterogeneity and therapeutic vulnerabilities in cancer biology.

This research article explores intelligent CpG nanoplatforms as an innovative approach to targeted cancer immunotherapy and immune microenvironment remodeling. The study, authored by Wang, Zhang, and Zhou, examines how CpG oligonucleotides integrated into nanoplatform systems can enhance immunogenic cell death and strengthen anti-tumor immune responses. By leveraging nanotechnology to deliver immunostimulatory agents directly to tumor sites, these intelligent platforms represent a significant advancement in precision oncology. The work addresses the critical challenge of modulating the tumor immune microenvironment to overcome immunosuppression, thereby improving therapeutic efficacy. This research contributes valuable insights into the development of next-generation cancer treatments that combine nanotechnology with immunological principles.

This article examines nano-immunotherapy strategies targeting tumor-associated macrophages (TAMs), which play a critical role in creating an immunosuppressive tumor microenvironment. Nano-drug delivery systems have emerged as multimodal platforms capable of delivering multiple drugs synergistically while incorporating physical energy interventions, thereby improving drug targeting and biocompatibility. The primary focus of TAM-targeted nano-immunotherapy is the precise regulation and functional remodeling of TAMs to reverse immunosuppression and inhibit cancer progression. The review addresses current knowledge gaps and challenges in this emerging field while exploring recent advances in nano-immunotherapy approaches specifically designed to modulate TAM function.

Researchers have developed innovative smart polymeric nanoparticles that respond to specific tumor microenvironment signals to deliver immunotherapy with precision, addressing a critical challenge in cancer treatment. These nanoparticles activate in response to acidic pH, elevated enzymes, reactive oxygen species, and other tumor-specific markers, triggering controlled drug release directly at cancer sites. The breakthrough converts immunologically 'cold' tumors, which lack immune cell infiltration and resist standard therapies, into 'hot' tumors capable of immune response. This targeted approach significantly enhances antitumor immunity while minimizing systemic toxicity and off-target effects associated with conventional immunotherapies. The advancement promises to extend effective cancer treatment to patient populations previously unresponsive to existing immunotherapy options.

Glioblastoma multiforme remains one of the most challenging brain tumors to treat, with limited drug efficacy largely due to the blood-brain barrier's impermeability and tumor heterogeneity. Despite FDA approval of only a few agents including temozolomide and bevacizumab, therapeutic outcomes remain modest and drug resistance persists. Biomaterial-based delivery systems have emerged as promising alternatives, leveraging their biodegradability and capacity to enhance blood-brain barrier penetration while promoting drug accumulation at tumor sites. This review comprehensively examines natural and synthetic biomaterials, evaluating their physicochemical properties, advantages for fabricating delivery systems, and limitations in preclinical and clinical applications. Additionally, it provides an extensive overview of biomaterials functionalized with therapeutic agents, detailing their composition and delivery strategies to improve glioblastoma treatment efficacy.